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Original Article
Readmissions in adult patients following hospitalization for 
influenza: a nationwide cohort study 
Srikanth Yandrapalli, Wilbert S. Aronow, William H. Frishman
Department of Medicine, New York Medical College at Westchester Medical Center, Valhalla, NY, USA
Contributions: (I) Conception and design: All authors; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) 
Collection and assembly of data: None; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of 
manuscript: All authors.
Correspondence to: Srikanth Yandrapalli, MD. Division of Internal Medicine, Westchester Medical Center, 100 Woods Road, Taylor Pavilion, Valhalla, 
NY 10595, USA. Email: srikanth.yn@gmail.com.
Background: Influenza epidemics are a major health care concern in the US. Influenza related 
complications can increase in-hospital complications, and readmissions following a hospitalization for 
influenza. We sought to determine the 30-day readmission rate, etiologies, outcomes, and healthcare burden 
of 30-day readmissions in adults hospitalized for influenza. 
Methods: The 2014 US National Readmissions Database (NRD) was retrospectively analyzed to identify 
patients ≥18 years of age hospitalized for influenza and discharged between January and November 2014. 
We used this time frame as this was the most recent data available for analysis and included patients who had 
30-day follow-up. Survey design based multivariable logistic regression models were used to identify factors 
associated with a 30-day readmission.
Results: Of the 46,117 patients who were hospitalized for influenza and survived to discharge, 4,721 (10.2%) 
patients had 5,275 30-day readmissions, estimated to 11.4 readmissions per 100 patients. Non-influenza 
pneumonia was the most common etiology of 30-day readmissions (10.4%) followed by sepsis (9.8%). The 
median costs of readmissions were $8,538 (IQR, $5,053–15,262), which were significantly higher than the 
median costs of their index hospitalizations [$7,863 (IQR, $4,875–13,212); P<0.001]. Around 6.5% of the 
patients died during a readmission.
Conclusions: Adult patients hospitalized for influenza had 11.4 30-day readmissions per 100 patients, 
most commonly for non-influenza pneumonia. Thirty-day readmissions were associated with higher costs of 
care and considerable mortality.
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Submitted Apr 20, 2018. Accepted for publication Jul 19, 2018.
doi: 10.21037/atm.2018.07.18
View this article at: http://dx.doi.org/10.21037/atm.2018.07.18
Introduction
Influenza is a major public health problem in the US 
with significant variations in its annual incidence and 
public health burden (1). While the majority of influenza 
patients are managed in the ambulatory setting, influenza 
and related complications can result in hospitalizations 
(1,2). The Center for Disease Control (CDC) reported 
an estimated minimum 140,000 and maximum 710,000 
hospitalizations for influenza and related complications 
between years 2010 and 2016 in the US (1,2). In the US 
in year 2003, influenza-related hospitalizations amounted 
to $6.0 billion in costs, which were only 7% of the total 
economic burden of influenza during that year (3). Among 
adult patients hospitalized for influenza, more than two-
thirds have underlying medical conditions, most commonly 
cardiovascular (CV) disease, metabolic disorder, obesity, 
and chronic lung disease (4). Further, available data 
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suggest an increased risk of adverse CV events like acute 
myocardial infarction (AMI) and ischemic cerebrovascular 
events (CVEs) in the acute phase following an influenza 
infection (5-14). 
While such risk of increased adverse events can increase 
in-hospital complications, they can also cause readmissions 
in these patients in the acute phase following influenza 
infection. Readmissions are usually measured within 30 
days because readmissions and deaths after a longer time 
period may be less influenced by the admitting condition 
and care gotten in the hospital and more to do with other 
complicating illnesses, patients’ behavior, or care provided 
to patients after hospital discharge (15). Data are scarce 
regarding the etiology and burden of 30-day readmissions 
following a hospitalization for influenza. We sought to 
determine the 30-day readmission rates and associated 
factors, reasons for readmission and their healthcare 
burden, after hospitalization for either influenza-pneumonia 
or influenza-related organ system manifestations in adult 
patients. 
Methods
Data source
In this retrospective observational study, data were collected 
from the publicly available 2014 US National Readmissions 
Database (NRD). The NRD is part of the Healthcare 
Cost and Utilization Project (HCUP) that is sponsored 
by the Agency for Healthcare Research and Quality 
(AHRQ) and is a database of all-payer hospital inpatient 
stays that can be used to generate national estimates of 
readmissions (16). The NRD is drawn from HCUP 
State Inpatient Databases which contain verified patient 
linkage numbers that can be used to track a person across 
readmissions while maintaining privacy. The NRD includes 
community hospitals and excludes rehabilitation or long-
term acute care hospitals. Unweighted, the 2014 NRD 
contains data from approximately 15 million discharges from 
22 partner states: Arkansas, California, Florida, Georgia, 
Hawaii, Iowa, Louisiana, Maryland, Massachusetts, 
Missouri, Nebraska, New Mexico, Nevada, New York, 
South Carolina, South Dakota, Tennessee, Utah, Virginia, 
Vermont, Washington, and Wisconsin. These states are 
geographically dispersed and account for 51.2% of the total 
US resident population and 49.3% of all hospitalizations. 
Weighted, it estimates roughly 35 million discharges (16). 
The NRD was post-stratified by hospital characteristics 
(census region, urban/rural location, hospital teaching 
status, size of the hospital defined by the number of beds, 
and hospital control) and patient characteristics [sex and five 
age groups (0, 1–17, 18–44, 45–64, and 65 and older)] (16). 
Discharge weights (variable DISCWT) were provided to 
obtain national estimates.
Patient population and baseline characteristics
The study sample included all adult patients (≥18 years) 
who were discharged alive between January and November 
2014 with a primary discharge diagnosis of influenza 
pneumonia or other influenza-related manifestations. 
These cases formed our index cohort. Patients discharged 
in December were excluded because the NRD design will 
not allow for 30-day follow-up of patients discharged in 
this month. International Classification of Diseases, Ninth 
Edition, Clinical Modification (ICD-9-CM) diagnosis codes 
487 and 488 were used to identify influenza diagnoses. 
We chose data from 2014 for our study as these were the 
most recently available data which used ICD-9 codes 
throughout for coding diagnosis. If a patient had multiple 
hospitalizations for influenza during the study period, only 
the first hospitalization for influenza was included in the 
index cohort. We did not include hospitalizations with a 
secondary discharge diagnosis of influenza because such 
hospitalizations could include patients with previously 
diagnosed influenza, co-incidental influenza diagnosis, and 
also hospital-acquired influenza when admitted for other 
reasons.
Baseline patient characteristics identified in the index 
cohort were age, sex, primary expected payer, median 
household income, comorbidities (anemia, atrial fibrillation, 
cancer, chronic lung disease, coagulopathy, depression, 
drug abuse, dementia, diabetes mellitus, hypertension, 
hypothyroidism, fluid-electrolyte imbalances, liver disease, 
obesity, other neurological disorders, paralysis, psychoses, 
peripheral vascular disease, pulmonary circulation 
disorders, chronic renal failure, and heart failure), in-
hospital complications [septicemia and shock, AMI, 
acute kidney injury (AKI), ischemic stroke and transient 
cerebral ischemic events, gastrointestinal hemorrhage, 
and respiratory failure), type and day of admission, and 
discharge disposition. Hospital characters (location, bed-
size, and teaching status) were also identified. Elixhauser 
comorbidity data were extracted from the NRD. ICD-
9-CM and the HCUP Clinical Classification Software 
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(CCS) codes used to identify comorbidities and in-hospital 
complications are available in Table S1. 
Study outcomes
The primary outcomes of this study were the 30-day 
readmission rate from the day of discharge, etiology 
for readmission, and the factors associated with 30-day 
readmissions. Secondary outcomes were comparison of 
length of stay (LOS) and costs of care between index 
hospitalization and readmission, and all-cause in-hospital 
mortality during 30-day readmissions only because all 
patients in our index cohort survived to discharge. LOS and 
costs of hospitalization were identified in both index cases 
and readmission, whereas, all-cause inpatient mortality was 
identified in 30-day readmissions. Methodology described 
by the HCUP to identify readmissions was used to 
identify 30-day readmissions (16). Total number of 30-day 
readmissions and the number of index-patients readmitted 
within 30-day were identified and expressed as proportion 
of the index hospitalizations. Time to readmission was 
calculated as the duration between index-hospital discharge 
and the first day of hospital readmission. 
Etiologies of  readmissions were recognized by 
identifying the ICD-9-CM diagnosis codes and the HCUP 
CCS codes of the primary discharge diagnosis of each 
individual readmission (available in Table S2). Causes of 
readmissions were classified on the basis of organ system 
involvement into respiratory, CV, infection-related, 
neurovascular, peripheral vascular, hematologic and 
cancer related, gastrointestinal, renal and fluid-electrolyte 
disorders, endocrine and metabolic, neuropsychiatric 
and substance abuse-related, musculoskeletal and injury 
related, symptom related (fever of unknown origin, malaise, 
abdominal pain, nausea/vomiting), complication of device-
graft-implant, or others. Respiratory causes included non-
influenza pneumonia and empyema, influenza, obstructive 
lung disease, pleural disease, respiratory failure, aspiration 
pneumonitis, and others. CV causes included heart failure, 
arrhythmias and conduction disorders, AMI, hypertension, 
coronary artery disease, pulmonary embolism, syncope, 
and chest pain. Infection-related etiologies included sepsis, 
intestinal infections, skin infections, urinary tract infections 
(UTIs), and others.
To identify costs of hospitalization, hospital reported 
charges (variable TOTCHG) were multiplied with the cost-
to-charge ratios developed and reported by the AHRQ. 
Statistical analysis
All statistical analyses were performed using IBM SPSS 
Statistics 25.0 (IBM Corp., Armonk, NY, USA). Weighted 
data were used for all statistical analyses. Categorical 
variables are expressed as percentages, and continuous 
variables as mean ± standard deviation (SD). Because the 
distributions of LOS and total hospital costs were skewed 
to the right, median [interquartile range (IQR)] were also 
reported. Baseline patient characters, comorbidities and 
complications, and hospital characteristics were compared 
between patients with and without 30-day readmission 
using Pearson χ2 test for categorical variables and student 
t-test for continuous variables. Nonparametric Mann-
Whitney U test was used to compare medians between 
patient groups. Since the NRD has a complex semi-
random multistage sampling survey design, survey design 
based multivariable logistic regression model [designed to 
test for 95% confidence intervals (CIs) and a two-sided P 
value threshold of <0.05] was designed to identify factors 
associated with 30-day readmissions. The regression model 
included all the variables which achieved a P value <0.2 in 
unadjusted analysis. In the NRD, patients’ aged ≥90 years 
were reported as 90-year-old. This can affect the results 
when age (in years) is used as a covariate in statistical 
analysis. Hence, patients were sub grouped into three age 
categories (18–44, 45–64, and ≥65 years). LOS of index 
hospitalizations was included in the regression model as a 
categorical variable divided into 2 groups based on median 
LOS cut-off. Results of the logistic regression analyses were 
reported as odds ratios (ORs) and 95% CIs.
Around ≤1% data were missing for the variables 
primary payer status, median household income, discharge 
disposition, and type of admission (elective versus non-
elective). Missing values were replaced with the dominant 
categories. Total hospital charge data were missing for 
around 1% index-hospitalizations and 0.9% of the 30-day 
readmission. Reported cost data were for the remainder of 
the cases.
Results 
Baseline characteristics of the study cohort and in-hospital 
complications
The index-study cohort included 46,117 adult patients 
who had influenza hospitalization meeting our index-case 
criteria and survived to discharge. These patients had a 
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mean age ± SD of 61.1±17.9 years and 53.6% were female. 
Of these, 22,457 (48.7%) were primarily hospitalized for 
influenza-pneumonia, 22,375 (48.5%) for influenza-related 
respiratory symptoms, and 1,285 (2.8%) for other organ-
system manifestations of influenza. Overall, around 44.5% 
patients were elderly with age ≥65 years. Baseline patient 
demographics, comorbidities, in-hospital complications, 
and hospital characteristics for the overall index-study 
cohort are presented in Table 1. More patients (31.1%) were 
in the lowest median income quartile ($1–39,999) group 
and around two-thirds had either Medicare or Medicaid 
health insurance. Hypertension, chronic pulmonary disease, 
diabetes mellitus, fluid-electrolyte disturbances, and anemia 
were the most prevalent comorbidities. While respiratory 
failure occurred in 22.1% of index hospitalizations, AKI 
complicated 12.8%, an AMI in 1.2%, and ischemic CVE in 
0.3%. More patients in the index-cohort were hospitalized 
in large-sized urban-based teaching hospitals. Median 
LOS was relatively short at 3 days [IQR, 2–6 days] and 
mean LOS ± SD was 5.1±6.9 days. The total costs of index 
hospitalizations were $489.9 million, mean $10,729±22,255 
and median $6,082 (IQR, $3,921–10,220).
Thirty-day readmissions and characteristics of index 
hospitalizations by readmission status
Of the 46,117 index-group patients, 4,721 (10.2%) patients 
had 5,275 30-day readmissions. This estimates to 11.4 
readmissions per 100 patients within a 30-day period from 
discharge. Baseline patient demographics, comorbidities, 
in-hospital complications, and hospital characters for the 
index cases with and without a readmission are presented in 
Table 1. 
Patients who had a 30-day readmission were generally 
older (63.9±17.5 years) compared to those without a 
30-day readmission (60.7±17.9 years; P=0.02), more likely 
to be insured by Medicare/Medicaid (74.9% vs. 64.6%; 
P<0.001), and more likely to have a higher burden of 
comorbidities and in-hospital complications. Ischemic 
CVEs (0.6% vs. 0.3%; P=0.005), AMI (2.1% vs. 1.2%; 
P<0.001), and gastrointestinal bleeding (1.4% vs. 0.7%; 
P<0.001) occurred almost two-times the rate in patients 
who had a 30-day readmission compared to those who did 
not. Patients who had a 30-day readmission had a longer 
median initial LOS [4 days (IQR, 3–7 days) vs. 3 days 
(IQR, 2–5 days); P<0.001], more likely to be discharged to 
a nursing home or other medical facility (20.4% vs. 12.3%; 
P<0.001) and had higher median index hospitalization costs 
[$7,863 (IQR $4,875–13,212) vs. $5,946 ($3,830–9,804); 
P<0.001]. 
Factors associated with a 30-day readmission
In multivariable logistic regression analysis results presented 
in Table 2, presence of chronic pulmonary disease (OR 1.15; 
95% CI, 1.03–1.27), drug abuse (OR 1.53; 95% CI, 1.18–
1.99), liver disease (OR 1.47; 95% CI, 1.12–1.92), chronic 
renal failure (OR 1.42; 95% CI, 1.23–1.64), heart failure 
(OR 1.45; 95% CI, 1.25–1.69), AKI (OR 1.24; 95% CI, 
1.07–1.44), anemia (OR 1.32; 95% CI, 1.17–1.50), cancer 
(OR 1.93; 95% CI, 1.56–2.39), and sepsis (OR 1.31; 95% 
CI, 1.01–1.68) were associated with a 30-day readmission. 
A longer LOS >3 days (OR 1.48; 95% CI, 1.31–1.67), 
discharge to nursing home/other medical facility (OR 1.23; 
95% CI, 1.07–1.44), and admission to a teaching hospital 
(OR 1.15; 95% CI, 1.03–1.29) also predicted a 30-day 
readmission.  
Timing and causes of 30-day readmissions
Of the 5,275 readmissions, 45.8% were within 10 days 
from discharge, 29.3% between days 11–20, and 24.8% 
between days 21–30. Median time to readmission was 
12 days (IQR, 5–20 days). Etiologies of readmissions 
were presented in Table 3. When stratified according 
to organ-system involvement, most common causes of 
30-day readmission were respiratory (31.2%), infectious 
(15.8%), CV (14.9%), gastrointestinal (7.6%), and 
hematologic-cancer related (4.9%). Diagnosis wise, non-
influenza pneumonia was the most common etiology of 
30-day readmissions (10.4%), followed by sepsis (9.8%), 
obstructive lung disease (8.0%), heart failure (6.2%), AKI 
and UTIs at 2.3% each. While a microbiological diagnosis 
was not made in most non-influenza pneumonias (78.4%), 
methicillin-resistant Staphylococcus aureus (MRSA) was the 
most frequently identified organism (4.8%) in the rest. 
Similarly, around 81% of the sepsis-related admissions did 
not have a microbiologic diagnosis, but when an organism 
was identified, it was more often gram-positive (12%; 5% 
streptococcal and 4% MRSA). 
LOS, costs, and mortality related to 30-day readmissions
Overall, 6.5% of the patients readmitted within 30-days 
from discharge died during a readmission. Mortality was 
highest when the readmission etiology was infectious, 
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Table 1 Baseline characteristics, comorbidities, in-hospital complication, and outcomes of patients in the index-cohort with and without a 30-day 
readmission
Baseline characteristics Total, % (N=46,117)
30-day readmission
P value
No, % (N=41,396) Yes, % (N=4,721)
Patient variables
Age (years) <0.001
18–44 18.7 19.2 14.2
45–64 36.8 37.1 34.1
65 and above 44.5 43.7 51.7
Sex 0.081
Female 53.6 53.8 52.4
Male 46.4 46.2 47.6
Median household income 0.394
$1–39,999 31.1 31.2 30.2
$40,000–50,999 26.4 26.2 27.6
$51,000–65,999 21.9 22.0 20.7
$66,000 or more 20.7 20.6 21.5
Primary payer <0.001
Medicare/Medicaid 65.7 64.6 74.9
Private 25.4 26.1 19.6
Uninsured 6.6 6.9 3.8
Others 2.3 2.4 1.8
Comorbidities
Anemia 17.5 16.4 26.4 <0.001
Atrial fibrillation 13.1 12.5 18.5 <0.001
Cancer 5.1 4.7 8.9 <0.001
Chronic pulmonary disease 40.3 39.9 43.6 <0.001
Chronic renal failure 15.6 14.4 25.8 <0.001
Coagulopathy 8.0 7.7 9.9 <0.001
Heart failure 15.1 13.9 25.5 <0.001
Dementia 7.8 7.5 10.3 <0.001
Depression 13.1 12.8 15.2 <0.001
Diabetes mellitus 30.0 29.4 35.5 <0.001
Drug abuse 3.3 3.2 4.6 <0.001
Fluid and electrolyte disorders 41.7 41.5 43.3 0.021
Hypertension 58.9 58.2 64.8 <0.001
Hypothyroidism 13.0 12.8 14.3 0.004
Liver disease 2.8 2.7 4.4 <0.001
Obesity 16.6 16.8 15.4 0.019
Other neurological disorders 9.7 9.4 11.6 <0.001
Table 1 (continued)
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Table 1 (continued)
Baseline characteristics Total, % (N=46,117)
30-day readmission
P value
No, % (N=41,396) Yes, % (N=4,721)
Paralysis 2.3 2.2 3.2 <0.001
Peripheral vascular disease 4.4 4.1 6.4 <0.001
Psychoses 5.2 5.1 6.0 0.006
Pulmonary circulation disorders 4.2 3.9 6.8 <0.001
In-hospital complications
AMI 1.2 1.1 2.1 <0.001
AKI 12.8 12.1 19.7 <0.001
Sepsis and shock 2.8 2.6 4.4 <0.001
Respiratory failure 22.1 21.4 28.2 <0.001
Gastrointestinal hemorrhage 0.8 0.7 1.4 <0.001
Ischemic CVE 0.3 0.3 0.6 0.005
Median LOS 3 days 3 days 4 days <0.001
≤3 days 51.9 53.5 37.4
>3 days 48.1 46.5 62.6
Admission day 0.026
Weekday 74.2 74.0 75.5
Weekend 25.8 26.0 24.5
Admission type 0.110
Elective 4.6 4.6 4.1
Disposition <0.001
Home 86.9 87.7 79.6
Short term hospital, nursing home, 
or other facility
13.1 12.3 20.4
Hospital characteristics
Location 0.001
Rural 4.6 4.7 3.6
Urban 95.4 95.3 96.4
Teaching status <0.001
Non-teaching 40.6 41.1 35.9
Teaching 59.4 58.9 64.1
Bed size <0.001
Small 18.7 19.0 16.4
Medium 27.8 27.8 27.6
Large 53.5 53.3 56.0
Median cost of care (US $) 6,082 5,946 7,863 <0.001
AMI, acute myocardial infarction; AKI, acute kidney injury; LOS, length of stay; CVE, cerebrovascular event.
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Table 2 Results of the multivariable regression analysis to identify factors associated with increased 30-day readmissions
Factors Reference category Multivariable analysis*, OR (95% CI)
LOS >3 days LOS ≤3 days 1.48 (1.31–1.67)
Sepsis and septic shock Absent 1.31 (1.01–1.68)
Cancer Absent 1.93 (1.56–2.39)
Anemia Absent 1.32 (1.17–1.50)
AKI Absent 1.24 (1.07–1.44)
Heart failure Absent 1.45 (1.25–1.69)
Chronic renal failure Absent 1.42 (1.23–1.64)
Liver disease Absent 1.47 (1.12–1.92)
Drug abuse Absent 1.53 (1.18–1.99)
Chronic pulmonary disease Absent 1.15 (1.03–1.27)
Discharge to nursing home/other facility Home discharge 1.24 (1.07–1.44)
Teaching hospital Non-teaching hospital 1.15 (1.03–1.29)
Private insurance Medicare/Medicaid 0.85 (0.74–0.97)
Uninsured Medicare/Medicaid 0.67 (0.52–0.85)
Obesity Non-obese 0.82 (0.69–0.96)
Age (years)
45–64 18–44 1.02 (0.85–1.23)
65 and above 18–44 1.01 (0.84–1.21)
Male sex Female sex 1.02 (0.93–1.13)
AMI Absent 1.08 (0.75–1.56)
Ischemic CVE Absent 1.05 (0.45–2.47)
Atrial fibrillation Absent 1.10 (0.95–1.28)
Coagulopathy Absent 1.04 (0.87–1.24)
Hypertension Absent 1.01 (0.90–1.13)
Hypothyroidism Absent 0.98 (0.83–1.15)
Depression Absent 1.13 (0.97–1.32)
Dementia Absent 1.06 (0.87–1.29)
Diabetes mellitus Absent 1.12 (0.99–1.26)
Gastrointestinal bleed Absent 1.33 (0.87–2.05)
Fluid and electrolyte disorder Absent 0.93 (0.84–1.04)
Other neurological disorder Absent 1.09 (0.92–1.30)
Paralysis Absent 1.28 (0.95–1.74)
Peripheral vascular disease Absent 1.09 (0.88–1.34)
Psychoses Absent 1.14 (0.91–1.44)
Pulmonary circulation disorders Absent 1.22 (0.99–1.49)
Table 2 (continued)
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Table 2 (continued)
Factors Reference category Multivariable analysis*, OR (95% CI)
Respiratory failure Absent 1.12 (0.98–1.28)
Elective admission Non-elective admission 0.95 (0.72–1.26)
Weekend admission Weekday admission 0.89 (0.79–1.01)
Rural-based hospital Urban-based hospital 1.02 (0.74–1.39)
Bed size of hospital
Large Small 1.15 (0.99–1.33)
Medium Small 1.16 (0.99–1.37)
*, survey design based multivariable logistic regression model designed to test for 95% confidence intervals and a two-sided P value 
of <0.05. OR, odds ratio; CI, confidence intervals; LOS, length of stay; AKI, acute kidney injury; AMI, acute myocardial infarction; CVE, 
cerebrovascular event.
Table 3 System based and disease specific etiologies of 30-day 
readmission after hospitalization for influenza
Etiology of readmission
30-day readmissions 
(N=5,275, %)
Respiratory 1,643 (31.1)
Non-influenza pneumonia and empyema 549 (10.4)
Influenza 190 (3.6)
Chronic obstructive lung disease and 
asthma
422 (8.0)
Aspiration pneumonitis 127 (2.4)
Pleural disease 32 (0.6)
Respiratory failure 223 (4.2)
Other respiratory tract disease 100 (1.9)
Cardiovascular 784 (14.9)
Heart failure 327 (6.2)
Conduction disease and arrhythmias 127 (2.4)
Acute myocardial infarction 63 (1.2)
Coronary artery disease 37 (0.7)
Hypertension 63 (1.2)
Pulmonary embolism 84 (1.6)
Syncope 32 (0.6)
Nonspecific chest pain 42 (0.8)
Infection-related and septicemia 835 (15.8)
Septicemia and shock 516 (9.8)
Intestinal infection 92 (1.7)
Urinary tract infections 119 (2.3)
Table 3 (continued)
Table 3 (continued)
Etiology of readmission
30-day readmissions 
(N=5,275, %)
Skin and soft-tissue infection 60 (1.1)
Others 42 (1.0)
Neurovascular 104 (2.0)
Ischemic cerebrovascular events 59 (1.1)
Peripheral vascular 91 (1.7)
Endocrine and metabolic 119 (2.3)
Gastrointestinal 402 (7.6)
Gastrointestinal hemorrhage 106 (2.0)
Renal diseases and fluid/electrolyte 
imbalance
243 (4.6)
Acute kidney injury 119 (2.3)
Fluid and electrolyte disorder 96 (1.8)
Neuropsychiatric and substance-related 242 (4.6)
Musculoskeletal and injury related 229 (4.3)
Symptom-related 109 (2.0)
Fever of unknown origin 38 (0.7)
Nausea/vomiting 22 (≤0.5)
Abdominal pain 28 (≤0.5)
Malaise and fatigue 15 (≤0.5)
Device, implant, graft complications 129 (2.4)
Others 90 (1.7)
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reaching a high of 21.5% in patient admitted for septicemia. 
Median LOS was 4 days (IQR, 3–8 days) with a mean of 
6.5±7.6 days. Total costs associated with 30-day readmissions 
were around $77.2 million during the study period. Median 
readmission costs were $8,538 (IQR, $5,053–15,262) and 
mean costs were $14,772±23,348. The median LOS of 
the readmissions (4 days) was significantly higher than the 
median LOS of all index admissions (3 days; P<0.001), but 
was similar to the median LOS of the index cases which had 
a readmission (4 vs. 4 days; P=0.77). The median costs of 
readmissions ($8,538) were significantly higher compared to 
median costs of all index cases ($6,082; P<0.001) and index 
cases with a 30-day readmission ($7,863; P<0.001).
Discussion
In this retrospective observational study of a large group 
of patients who were representative of the US population 
and were primarily hospitalized for influenza in 2014, a 
substantial number of patients were readmitted within 
30-days from discharge, with an estimated 11.4% 
readmission rate. 
Respiratory system diseases and infections were the most 
common etiologies for a 30-day readmission. Influenza 
infection increases the risk of secondary pneumonias’ 
particularly bacterial (17). In our study, non-influenza 
pneumonia was the most common cause of 30-day 
readmissions. A microbiological diagnosis was not made in 
around four-fifths of the cases in our study, but the most 
commonly identified organism was MRSA in 5%. During 
influenza epidemics, both Streptococcus pneumonia and 
Staphylococcus aureus (more recently MRSA) were identified 
as common causes of bacterial pneumonias (17). 
Prior studies have reported an increased risk of AMI 
and stroke in the acute phase following influenza (5-7,9-
11,13,14,18,19). In our study, AMI and ischemic CVEs 
had incident rates of 1.2% and 0.3% respectively and were 
infrequent causes of 30-day readmissions (between 1–2%). 
However, it must be noted that we only included patients 
who survived to discharge during an index hospitalization 
in our analysis and the hence did not fully capture incidence 
rate of AMI or ischemic CVEs in all adults hospitalized 
for influenza. Influenza infection has not been clearly 
implicated to cause heart failure and obstructive lung 
disease exacerbations (20-22). In our study, hospitalizations 
for heart failure, chronic obstructive pulmonary disease, and 
asthma were important causes 30-day readmissions. 
In our study, increasing age categories and differences 
in sex did not influence 30-day readmission risk. Anemia, 
cancer, heart failure, chronic lung disease, liver disease, 
and chronic renal failure independently predicted a 
30-day readmission. These conditions increase the 
comorbid disease burden in patients and can result in 
multiple hospitalizations. AMI and ischemic CVEs, which 
occurred infrequently in our index group patients, were 
not associated with a 30-day readmission. Interestingly, 
LOS more than 3 days was independently associated with a 
readmission. A longer LOS might suggest a sicker patient 
but a LOS higher than the median predicted a readmission 
after accounting for common in-hospital complications and 
comorbidities. Patients had a higher 30-day readmission 
risk when discharged to a nursing home or other medical 
facility. Patients discharged to a nursing home should have 
more supervision of care to help reduce hospitalizations. 
However, patients typically discharged to a nursing facility 
are older with a higher comorbidity burden and severity of 
illness associated with increased readmissions (23). Early 
and appropriate discharge planning to reduce LOS and to 
aim for home-discharge with adequate support might help 
reduce the readmission rate in this patient group. 
Readmissions also represented a significant health-care 
and economic burden. Among patients hospitalized within 
30 days from discharge, 6.5% died. More patients died 
when the cause of readmission was infectious. Appropriate 
infection control strategies during index hospitalization 
and early identification and treatment of septicemia should 
be emphasized to decrease this high mortality rate. The 
economic burden of readmissions was higher than the index 
admissions despite having a similar LOS. These findings 
suggest higher health-care resource utilization during 
readmissions. 
The strengths of our study are utilization of a large 
nationally representative administrative database which 
was collected using validated methods to reduce selection 
bias. Using validated methodology, we were able to 
determine the 30-day readmission rates, identify the 
causes and predictors of readmissions, and determine their 
economic impact in the real-world patients hospitalized for 
influenza (16). 
Our study has important limitations. Firstly, administrative 
databases lack clinical and laboratory variables which can more 
accurately determine duration of infection and patient status. 
It is not known if influenza was diagnosed based on clinical 
symptoms or laboratory testing in our study. Secondly, 
using billing codes to identify causes of hospitalizations 
and in-hospital complications can result in misclassification 
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bias. Thirdly, data on anti-influenza medication use and 
vaccination was not available. We were unable to test the 
association of immunization and anti-viral treatment on 
readmission risk. Fourthly, our sample included influenza 
patients across 2 different seasons (January–November) and 
excluded patients discharged in December. The design of 
the NRD, which is a yearly database, limited our ability to 
perform analysis bases on flu-season. We could not adjust 
for viral-strain and seasonal based differences in readmission 
rates. Lastly, the NRD does not report out of hospital and 
emergency room mortality data, which could influence the 
readmission rates. 
Conclusions
In conclusion, adult patients hospitalized for influenza had 
11.4 30-day readmissions per 100 patients, most commonly 
for non-influenza pneumonia and other infections. Thirty-
day readmissions were associated with significant healthcare 
impact with higher costs of care and considerable mortality. 
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Supplementary
Table S1 ICD-9CM and the CCS codes used to identify primary discharge diagnoses, baseline comorbidities, and in-hospital complications
Diagnosis ICD-9-CM codes CCS codes
Influenza 123
Influenza-pneumonia 487.0, 488.01, 488.11, 488.81
Other respiratory manifestations 487.1, 488.02, 488.12, 488.82
Other manifestations 487.8, 488.09, 488.19, 488.89
Comorbidities
Dementia 290.xx, 294.1x, 294.2x, 331.0, 331.1x,  
331.82, 331.89
Atrial fibrillation 427.31
In-hospital complications
Sepsis 788.52 2
Respiratory failure 131
Gastrointestinal hemorrhage 153
Acute myocardial infarction 410.x1, 411.1
Acute kidney injury 584.x
Ischemic stroke and transient 
cerebral ischemia
433.x1 112
x, the ICD-9CM subcode; ICD-9CM, International Classification of Diseases, Ninth Edition, Clinical Modification; CCS, Clinical 
Classification Software.
Table S2 ICD-9CM and the CCS codes in the primary discharge diagnosis position used to identify causes of 30-day readmissions
Organ system/diagnosis CCS codes ICD-9-CM codes
Respiratory 56, 122–134 
Pneumonia and empyema 122
Influenza 123
COPD and asthma 127, 128
Aspiration pneumonitis 129
Pleural disease 510.9, 511.0, 511.89, 511.9, 512.0, 
512.89
Respiratory failure 518.8x
Other respiratory tract disease 125,126,133,134
Cardiovascular 96–108, 245
Heart failure 108 402.91, 404.91, 404. 93, 788.51
Conduction disease and arrhythmia 105, 106, 107
AMI 100
CAD 101 414.04
Hypertension 98,99
Pulmonary embolism 415.1x
Syncope 245
Nonspecific chest pain 102
Neurovascular 109–113
Ischemic stroke and transient cerebral ischemia 112 434.11, 434.91
Peripheral vascular 114–121
Hematologic and cancer-related 14, 15, 16, 18, 19, 24, 33, 35, 38, 39, 40, 42, 44, 
45, 47, 59–63
Endocrine and metabolic 50, 51, 58
Gastrointestinal 138–141, 143–155
GIB 153
Renal diseases and fluid/electrolyte imbalance 55, 157,158, 160–163
AKI 584.x
Fluid and electrolyte disorders 55
Neuropsychiatric and substance-related 81, 83, 84, 85, 93, 95, 651, 653, 654, 657, 659, 
660, 661
MSK and injury related 54, 203–205, 207, 210–212, 226, 229–234, 238–
244
Symptoms
Fever of unknown origin 246
Nausea/vomiting 250
Abdominal pain 251
Malaise and fatigue 252
Device, implant, graft complications 237
Others 89, 92, 136, 137, 165–167, 
171,175,182,187,189,193, 199, 253, 254, 257, 259
x, the ICD-9CM subcode; ICD-9CM, International Classification of Diseases, Ninth Edition, Clinical Modification; CCS, Clinical 
Classification Software; COPD, chronic obstructive lung disease; AMI, acute myocardial infarction; CAD, coronary artery disease; UTI, 
urinary tract infection; AKI, acute kidney injury.
